Northern Trust’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-29,636
| Closed | -$8K | – | 4756 |
|
|
2022
Q3 | $8K | Hold |
29,636
| – | – | ﹤0.01% | 4659 |
|
|
2022
Q2 | $10K | Hold |
29,636
| – | – | ﹤0.01% | 4698 |
|
|
2022
Q1 | $20K | Hold |
29,636
| – | – | ﹤0.01% | 4671 |
|
|
2021
Q4 | $68K | Hold |
29,636
| – | – | ﹤0.01% | 4534 |
|
|
2021
Q3 | $135K | Hold |
29,636
| – | – | ﹤0.01% | 4321 |
|
|
2021
Q2 | $131K | Sell |
29,636
-147,393
| -83% | -$750K | ﹤0.01% | 4293 |
|
|
2021
Q1 | $1.29M | Sell |
177,029
-5,107
| -3% | -$42K | ﹤0.01% | 3475 |
|
|
2020
Q4 | $1.39M | Buy |
182,136
+47,058
| +35% | +$315K | ﹤0.01% | 3370 |
|
|
2020
Q3 | $1.23M | Sell |
135,078
-5,769
| -4% | -$43.8K | ﹤0.01% | 3302 |
|
|
2020
Q2 | $1.19M | Buy |
140,847
+39,870
| +39% | +$262K | ﹤0.01% | 3295 |
|
|
2020
Q1 | $499K | Buy |
100,977
+15,375
| +18% | +$120K | ﹤0.01% | 3447 |
|
|
2019
Q4 | $616K | Sell |
85,602
-323
| -0.4% | -$2.92K | ﹤0.01% | 3514 |
|
|
2019
Q3 | $929K | Sell |
85,925
-2,964
| -3% | -$31.7K | ﹤0.01% | 3412 |
|
|
2019
Q2 | $1.16M | Buy |
88,889
+938
| +1% | +$12.5K | ﹤0.01% | 3312 |
|
|
2019
Q1 | $869K | Buy |
87,951
+3,982
| +5% | +$37.1K | ﹤0.01% | 3405 |
|
|
2018
Q4 | $873K | Buy |
+83,969
| New | +$1.01M | ﹤0.01% | 3405 |
|
Northern Trust's LOGC Position: Q4 2022 in Review
Northern Trust sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 29,636 shares — an estimated $8K sold.
Northern Trust first reported a position in LOGC in Q4 2018 and held it in 16 quarters. The position peaked at $1.39M in Q4 2020. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.
- Northern Trust reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
- Northern Trust sold 29,636 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $8K.
- Northern Trust first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2018 and held it in 16 quarters.
- Northern Trust's LogicBio Therapeutics, Inc. Common Stock position peaked at $1.39M in Q4 2020.
- 0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.
Based on Northern Trust's 13F filing for Q4 2022, filed 13 Feb 2023.